190,568 Shares in Becton Dickinson and Co (BDX) Purchased by Marshall Wace North America L.P.
Marshall Wace North America L.P. purchased a new stake in Becton Dickinson and Co (NYSE:BDX) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 190,568 shares of the medical instruments supplier’s stock, valued at approximately $49,738,000. Marshall Wace North America L.P. owned approximately 0.07% of Becton Dickinson and as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in BDX. Acropolis Investment Management LLC purchased a new position in shares of Becton Dickinson and in the 3rd quarter valued at about $101,000. Almanack Investment Partners LLC. purchased a new position in shares of Becton Dickinson and in the 2nd quarter valued at about $105,000. Truvestments Capital LLC purchased a new position in shares of Becton Dickinson and in the 3rd quarter valued at about $105,000. Bridgeworth LLC purchased a new position in shares of Becton Dickinson and in the 2nd quarter valued at about $131,000. Finally, Sageworth Trust Co purchased a new position in shares of Becton Dickinson and in the 3rd quarter valued at about $147,000. Hedge funds and other institutional investors own 85.19% of the company’s stock.
Several brokerages recently weighed in on BDX. Wells Fargo & Co lifted their price target on Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a research note on Thursday, September 6th. They noted that the move was a valuation call. Piper Jaffray Companies cut their price target on Becton Dickinson and to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, November 6th. Barclays started coverage on Becton Dickinson and in a research note on Monday, October 15th. They set an “equal weight” rating and a $278.00 price objective for the company. KeyCorp boosted their price objective on Becton Dickinson and from $264.00 to $273.00 and gave the stock an “overweight” rating in a research note on Thursday, November 8th. Finally, Deutsche Bank started coverage on Becton Dickinson and in a research note on Thursday. They set a “buy” rating and a $280.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $255.53.
NYSE:BDX traded down $2.63 during trading hours on Friday, hitting $238.60. 12,735 shares of the stock were exchanged, compared to its average volume of 997,758. Becton Dickinson and Co has a 52-week low of $209.91 and a 52-week high of $265.87. The company has a current ratio of 1.03, a quick ratio of 0.69 and a debt-to-equity ratio of 0.90. The firm has a market cap of $65.70 billion, a P/E ratio of 21.64, a price-to-earnings-growth ratio of 1.69 and a beta of 1.21.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $2.93 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $2.93. The company had revenue of $4.40 billion during the quarter, compared to analyst estimates of $4.36 billion. Becton Dickinson and had a return on equity of 13.88% and a net margin of 1.47%. Becton Dickinson and’s quarterly revenue was up 39.0% on a year-over-year basis. During the same period in the previous year, the business earned $2.40 EPS. On average, research analysts forecast that Becton Dickinson and Co will post 12.1 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Monday, December 31st. Stockholders of record on Monday, December 10th will be issued a dividend of $0.77 per share. This is a boost from Becton Dickinson and’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a dividend yield of 1.29%. The ex-dividend date is Friday, December 7th. Becton Dickinson and’s payout ratio is currently 27.25%.
TRADEMARK VIOLATION WARNING: “190,568 Shares in Becton Dickinson and Co (BDX) Purchased by Marshall Wace North America L.P.” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/190568-shares-in-becton-dickinson-and-co-bdx-purchased-by-marshall-wace-north-america-l-p/2668096.html.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Story: What does relative strength index mean?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.